Brief reportEffects of menstrual phase on intake of nicotine, caffeine, and alcohol and nonprescribed drugs in women with late luteal phase dysphoric disorder
References (7)
Late luteal phase dysphoric disorder
- et al.
Alcoholism in women
Archives of General Psychiatry
(1971) C-DIS operations manual
(1991)
Cited by (48)
Estrous cycle modulates the anxiogenic effects of caffeine in the elevated plus maze and light/dark box in female rats
2021, Behavioural Brain ResearchDaily symptom ratings for studying premenstrual dysphoric disorder: A review
2016, Journal of Affective DisordersCitation Excerpt :Moreover, assessment of between-person differences is not suitable for revealing processes within persons. While several studies have used univariate repeated measures analysis to explore within-person variation in symptom levels across the various menstrual phases and across multiple cycles (Berger and Presser, 1994; Bloch et al., 1998, 1997; Eriksson et al., 2006; Marks et al., 1994; Marr et al., 2011a; Pearlstein et al., 2005c; Rapkin et al., 1998; Seippel and Bäckström, 1998; Sundblad et al., 1993; Wang et al., 1996), these studies only reveal mean symptom patterns within-persons, rather than individual patterns of symptom change across time. This is problematic, because results found at group level can only be generalised to the individual level under very strict conditions (Molenaar, 2004; Molenaar and Campbell, 2009), which are rarely met.
Illicit drug use, early age at first use and risk of premenstrual syndrome: A longitudinal study
2015, Drug and Alcohol DependenceCitation Excerpt :Although no consistent relation between the patterns of most abused drug use and menstrual cycle has been observed, there are studies showing increased drug use during late luteal phase in women with PMDD (Mello, 1986; Evans et al., 2002; Terner and de Wit, 2006). However there is also some evidence of a lack of intra-subject correlations between symptomatology and drug intake, and peak intake of illicit drugs failed to coincide with peak symptomatology in women with PMDD (Marks et al., 1994). The different trend observed for drug use in the last 12 months and PMS, and the different associations detected between age at first drug use and PMS in this study (significant association for early starters versus no association for later starters) provides little support for the self-medication hypothesis.
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
2011, Drug and Alcohol DependenceCitation Excerpt :Women are reported to have more difficulty quitting smoking than men, whether quitting without assistance (Kabat and Wynder, 1987; Ward et al., 1997) or with behavioral interventions or nicotine replacement therapy (Bjornson et al., 1995; Bohadana et al., 2003; Perkins, 2001; Perkins and Scott, 2008; Royce et al., 1997; Swan et al., 1997; Wetter et al., 1999). The contributing role of the menstrual cycle to the apparent reduced rate of smoking cessation for women has been supported by investigations showing higher rates of smoking during menses (DeBon et al., 1995; Marks et al., 1994; Steinberg and Cherek, 1989) and the luteal phase (DeBon et al., 1995; Mello et al., 1987; Snively et al., 2000), greater desire to smoke and reduce negative affect in luteal versus follicular phases (Allen et al., 1999), and more intense cue-induced craving in luteal versus follicular phases or compared to males (Franklin et al., 2004). Although some reports have not shown menstrual cycle phase effects on smoking withdrawal symptoms (Allen et al., 1999; Pomerleau et al., 2000), others have shown increased withdrawal symptoms and craving in the luteal phase (Allen et al., 2009; Carpenter et al., 2006; DeBon et al., 1995; O’Hara et al., 1989; Perkins et al., 2000; Pomerleau et al., 1992) as well as increases in self-reported depressive symptoms (Perkins et al., 2000).
Hormones, nicotine, and cocaine: Clinical studies
2010, Hormones and BehaviorInfluence of phase-related variability in premenstrual symptomatology, mood, smoking withdrawal, and smoking behavior during ad libitum smoking, on smoking cessation outcome
2009, Addictive BehaviorsCitation Excerpt :Despite inconsistencies in the literature, due in part to differences in methodology and difficulty separating premenstrual from withdrawal symptomatology, there is considerable support for the role of cycle-related hormonal changes in making quitting more difficult for women (see Carpenter, Upadhyaya, LaRowe, Saladin, & Brady, 2006 for a review). Attempts to assess the effects of menstrual cycle phase on ability to abstain from smoking have typically relied on either collection of data during ad libitum smoking followed by a time-limited period of attempted smoking abstinence (e.g., Allen, Hatsukami, Christianson, & Brown, 2000; Craig, Parrot, & Coomber, 1992; DeBon, Klesges, & Kleges, 1995; Franklin et al., 2004; Marks, Hair, Klock, Ginburg, & Pomerleau, 1994; Pomerleau, Garcia, Pomerleau, & Cameron, 1992) or on assessments collected in the context of a trial (e.g., O'Hara, Portser, & Anderson, 1989; Perkins et al., 2000). By contrast, the possible influence of individual differences in phase-related measures of premenstrual symptomatology, mood, and smoking withdrawal during ad libitum smoking upon smoking cessation outcome has been underexplored.
Data were collected by the first author as part of her doctoral dissertation at the University of Connecticut; the work was supported by a grant from the University of Connecticut Foundation to the fourth author and a grant from the University of Connecticut Health Center to the second author. Preparation of the article was supported Grant CA 42730 to Ovide F. Pomerleau by the National Cancer Institute. The authors wish to thank Nancy Reame for her helpful comments on an earlier draft of this manuscript.